US 7,547,715 B2
	Endogenous repair factor production accelerator
Yoshiki Sakai, Mishima-gun (Japan); Akio Nishiura, Mishima-gun (Japan); and Teppei Ogata, Mishima-gun (Japan)
Assigned to Ono Pharmaceutical Co., Ltd., Osaka (Japan)
Appl. No. 10/530,685 PCT Filed Oct. 09, 2003, PCT No. PCT/JP03/12981 § 371(c)(1), (2), (4) Date Apr. 08, 2005, PCT Pub. No. WO2004/032965, PCT Pub. Date Apr. 22, 2004.
Claims priority of application No. 2002-298079 (JP), filed on Oct. 10, 2002; application No. 2002-318830 (JP), filed on Oct. 31, 2002; and application No. 2003-117604 (JP), filed on Apr. 22, 2003.
Prior Publication US 2006/0069018 A1, Mar. 30, 2006
Int. Cl. A61K 31/44 (2006.01)

U.S. Cl. 514—353

6 Claims

1. A method of treating lung diseases selected from the group consisting of acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof.